BRAF and ganglioglioma: Key mutations driving these tumors include the KIAA1549-BRAF fusion, prevalent in pilocytic astrocytoma (approx. 70%) and rosette-forming glioneural tumors (approx. 30%) in non-NF1 patients, as well as BRAF V600E mutations, commonly found in pleomorphic xanthoastrocytoma (approx. 80%), ganglioglioma (approx. 45%), and pediatric-type diffuse low-grade gliomas (approx. 40%) [69,70,79,82,83,84].